Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amgen Reports Positive Results for Dazodalibep in Sjögren's Disease

Guavy AI Editorial Team
Instruments
AMGN
Share

Amgen Inc., a US-based biopharmaceutical company, has announced positive topline phase 3 results for its treatment dazodalibep in moderate-to-severe systemic Sjögren's disease. This announcement was made on September 22, 2026.

The stock price of Amgen remained unchanged at EUR 358.63 in weekend trading at Lang & Schwarz on October 4, 2026, marking a 0.00 percent change from the previous close of EUR 358.63 on October 2, 2026.

More on Stocks

Stocks just now

Microsoft's $678 Billion Backlog Sparks Revenue Timing Concerns

Stocks 9m ago

CoreWeave Stock: High Growth, High Risk

Stocks 13m ago

Iowa Student Misses Million-Dollar Field Goal, Earns Title of Worst Kicker Ever

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy